Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Gubra AS's 3-Year RORE % for the quarter that ended in Dec. 2025 was 108.22%.
The industry rank for Gubra AS's 3-Year RORE % or its related term are showing as below:
FRA:PI3's 3-Year RORE % is ranked better than 96.21% of 1293
companies
in the Biotechnology industry
Industry Median: -11.55
vs FRA:PI3: 108.22
Gubra AS (FRA:PI3) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Gubra AS 3-Year RORE % Related Terms
Gubra AS 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Gubra AS's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PI3 vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Gubra AS's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Gubra AS's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Gubra AS (FRA:PI3) has a 3-Year RORE % of 108.22 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Gubra AS and its competitors. According to the industry distribution chart, Gubra AS ranks #49 out of 1293 companies in the Biotechnology industry, placing it in the top 3.8%.
Is Gubra AS's 3-Year RORE % too high?
Gubra AS's current 3-Year RORE % is 108.22. Based on the distribution chart, Gubra AS ranks #49 out of 1293 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gubra AS has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #49 out of 1293 companies for 3-Year RORE %. This places Gubra AS in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Gubra AS and its competitors. Gubra AS's current 3-Year RORE % is 108.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €372.36, compared to a current price of €44.00 — trading 88.2% below its estimated fair value. The current 3-Year RORE % is 108.22. Gubra AS's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current 3-Year RORE % is 108.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (FRA:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued.
The current stock price of €44.00 is trading 88.2% below its estimated GF Value™ of €372.36.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for FRA:PI3:
3-Year RORE %: 108.22
GF Value™: €372.36 vs. price of €44.00 (88.2% below fair value)
No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
73GF Score
Get the complete analysis for FRA:PI3
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PI3 has been successfully added to your 
